Insider · CIK 0001567160
Kyle Gano
Files at NBIX (NEUROCRINE BIOSCIENCES INC). First filing Jan 17, 2025, latest Jan 20, 2026.
In brief
Kyle Gano files SEC Form 4 as CEO and director at NBIX (NEUROCRINE BIOSCIENCES INC). Since Jan 17, 2025, Kyle Gano has reported 0 open-market buys worth $0 and 6 open-market sells worth $15M, the latest filed on Jan 20, 2026.
A track record needs three past buys with six months of prices behind them; Kyle Gano has 0, so none is measured yet.
The newest scored trade: sold $4.8M of NBIX on Jan 16, 2026, filed Jan 20, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $4.9M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NBIX: NEUROCRINE BIOSCIENCES INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | NEUROCRINE BIOSCIENCES INC | $4.8M 36,400 shares | -21% | +51% from low-15% from high | |
| 4Weak | NEUROCRINE BIOSCIENCES INC | $43k 300 shares | -0% | +64% from low-7% from high | |
| 19Weak | NEUROCRINE BIOSCIENCES INC | $299k 2,558 shares | -2% | - | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | $116k 980 shares | -1% | - | |
| 18Weak | NEUROCRINE BIOSCIENCES INC | $236k 1,541 shares | -1% | - | |
| 33Weak | NEUROCRINE BIOSCIENCES INC | $9.2M 65,000 shares | -46% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | 36,400 0.04% of outstanding | $4.9M | Jan 16, 2026 | $43k |
| Nov 5, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 300 0.00% of outstanding | $43k | Nov 4, 2025 | none |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 1,352 0.00% of outstanding | $158k | Feb 13, 2025 | $9.5M |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 1,206 0.00% of outstanding | $141k | Feb 13, 2025 | $9.5M |
| Feb 10, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | 980 0.00% of outstanding | $120k | Feb 10, 2025 | $9.4M |
| Jan 31, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 1,541 0.00% of outstanding | $236k | Jan 31, 2025 | $9.2M |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES, INC. | 65,000 0.06% of outstanding | $9.1M | Jan 15, 2025 | none |
Transactions
The newest 50 of 51 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Common Stock | +6,275 | $0.00 | $0 | 157,266 | 28 d ago |
| Sep 11, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -3,386 | $156.22 | $529k | 153,880 | 28 d ago |
| Sep 11, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Common Stock | +1,842 | $0.00 | $0 | 155,722 | 28 d ago |
| Sep 11, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -994 | $156.22 | $155k | 154,728 | 28 d ago |
| Feb 12, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +4,907 | $0.00 | $0 | 146,661 | Feb 17, 2026 |
| Feb 12, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -2,648 | $123.10 | $326k | 144,013 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +2,241 | $0.00 | $0 | 146,254 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -1,210 | $124.12 | $150k | 145,044 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +2,566 | $0.00 | $0 | 147,610 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -1,385 | $124.12 | $172k | 146,225 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Common Stock | +9,968 | $0.00 | $0 | 156,193 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -5,378 | $124.12 | $668k | 150,815 | Feb 17, 2026 |
| Feb 12, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -4,907 | $0.00 | $0 | 14,721 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -2,241 | $0.00 | $0 | 4,484 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -2,566 | $0.00 | $0 | 2,566 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Stock Optionderivative | +114,830 | $0.00 | $0 | 114,830 | Feb 17, 2026 |
| Feb 13, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative | +20,142 | $0.00 | $0 | 20,142 | Feb 17, 2026 |
| Jan 31, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +2,927 | $0.00 | $0 | 143,334 | Feb 3, 2026 |
| Jan 31, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | FTax withholding Common Stock | -1,580 | $136.06 | $215k | 141,754 | Feb 3, 2026 |
| Jan 31, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -2,927 | $0.00 | $0 | 0 | Feb 3, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +34,588 | $35.99 | $1.2M | 174,995 | Jan 20, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -34,588 | $132.70 | $4.6M | 140,407 | Jan 20, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +1,812 | $35.99 | $65k | 142,219 | Jan 20, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -1,812 | $132.71 | $240k | 140,407 | Jan 20, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -34,588 | $0.00 | $0 | 0 | Jan 20, 2026 |
| Jan 16, 2026 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative10b5-1 | -1,812 | $0.00 | $0 | 0 | Jan 20, 2026 |
| Nov 1, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock | +613 | $0.00 | $0 | 140,720 | Nov 4, 2025 |
| Nov 4, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -300 | $141.97 | $43k | 140,407 | Nov 4, 2025 |
| Nov 1, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative | -613 | $0.00 | $0 | 1,842 | Nov 4, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +2,566 | $0.00 | $0 | 140,224 | Feb 14, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -1,352 | $116.84 | $158k | 138,872 | Feb 14, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +2,241 | $0.00 | $0 | 141,113 | Feb 14, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -1,206 | $116.86 | $141k | 139,907 | Feb 14, 2025 |
| Feb 12, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Stock Optionderivative10b5-1 | +104,736 | $0.00 | $0 | 104,736 | Feb 14, 2025 |
| Feb 12, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative10b5-1 | +19,628 | $0.00 | $0 | 19,628 | Feb 14, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -2,566 | $0.00 | $0 | 5,132 | Feb 14, 2025 |
| Feb 13, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -2,241 | $0.00 | $0 | 6,725 | Feb 14, 2025 |
| Feb 8, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +1,860 | $0.00 | $0 | 138,638 | Feb 12, 2025 |
| Feb 10, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -980 | $118.39 | $116k | 137,658 | Feb 12, 2025 |
| Feb 8, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -1,860 | $0.00 | $0 | 0 | Feb 12, 2025 |
| Jan 31, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +2,927 | $0.00 | $0 | 138,319 | Feb 4, 2025 |
| Jan 31, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -1,541 | $152.87 | $236k | 136,778 | Feb 4, 2025 |
| Jan 31, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Restricted Stock Unitderivative10b5-1 | -2,927 | $0.00 | $0 | 2,927 | Feb 4, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +4,812 | $32.99 | $159k | 140,204 | Jan 17, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -4,812 | $141.50 | $681k | 135,392 | Jan 17, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Common Stock10b5-1 | +60,188 | $32.99 | $2.0M | 195,580 | Jan 17, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | SOpen-market sale Common Stock10b5-1 | -60,188 | $141.50 | $8.5M | 135,392 | Jan 17, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Incentive Stock Optionderivative10b5-1 | -4,812 | $0.00 | $0 | 0 | Jan 17, 2025 |
| Jan 15, 2025 | NBIX NEUROCRINE BIOSCIENCES INC | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -60,188 | $0.00 | $0 | 0 | Jan 17, 2025 |
| Nov 1, 2024 | NBIX NEUROCRINE BIOSCIENCES INC | AGrant or award Restricted Stock Unitderivative | +2,455 | $0.00 | $0 | 2,455 | Nov 1, 2024 |
Questions about Kyle Gano
Answered from the filings on this page, as of the latest one.
Is Kyle Gano buying or selling?
In the last 12 months Kyle Gano reported 0 open-market buys worth $0 and 2 open-market sells worth $4.9M on SEC Form 4; the latest was sold $4.8M of NBIX on Jan 16, 2026. Grants, option exercises and tax withholding are not counted.
How did Kyle Gano's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kyle Gano has 0.
Where does Kyle Gano file Form 4?
Kyle Gano has filed Form 4 at NBIX (NEUROCRINE BIOSCIENCES INC) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.